By Bhanvi Satija and Marleen Kaesebier LONDON, April 28 (Reuters) - Novartis posted first-quarter core operating profit and ...
5don MSN
Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'
Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation." ...
Generic competition for Promacta, a blood disorder drug, and Tasigna, a leukemia treatment, is adding pressure on Novartis ...
Group operating income is down by 12% at US$4.9 billion, below analyst expectations of US$5.1 billion Read more at The ...
The stock is down on a predictable, already-announced Entresto patent cliff (Entresto -42% YoY in Q1) and the market is ...
Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.
A U.S. federal judge rejected Novartis' efforts to block the launch of a generic version of Entresto, its blockbuster cardiovascular disease drug, per a FirstWord PHARMA report. The report noted that ...
Novartis (NVS) stock dropped 2% as Q1 sales missed estimates at $13.11B. Entresto plunged 42% on generics while CEO warns of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results